517 results about "Triazole derivatives" patented technology

A light emitting element comprises a first electrode, a second electrode configured to transmitting light, an organic layer arranged between the first and the second electrodes, comprising a light emitting layer, and a capping layer arranged on the second electrode and made of a material with a higher refractive index than the refractive index of the material constituting the second electrode. The material constituting the capping layer comprises at least one selected from the group consisting of triarylamine derivative, carbazole derivative, benzimidazole derivative and triazole derivative.

A composition and associated method for chemical mechanical planarization (or other polishing) are described which afford high tantalum to copper selectivity in copper CMP and which are tunable (in relation to polishing performance). The composition comprises an abrasive and an N-acyl-N-hydrocarbonoxyalkyl aspartic acid compound and / or a tolyltriazole derivative.

Triazole derivatives of structural formula I are selective inhibitors of the 11β-hydroxysteroid dehydrogenase-1. The compounds are useful for the treatment of diabetes, such as noninsulin-dependent diabetes (NIDDM), hyperglycemia, obesity, insulin resistance, dyslipidemia, hyperlipidemia, hypertension, Metabolic Syndrome, and other symptoms associated with NIDDM.

The present invention is directed to the compound of formula I which is useful for inhibiting the activity of Factor Xa. The present invention is also directed to compositions containing said compounds, processes for their preparation, their use, such as for inhibiting the formation of thrombin or for therapeutically or prophylactically treating a patient suffering from, or subject to, or associated with a disease state associated with a cardiovascular disorder.

The present invention provides novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors according to formula (I) that are useful in the treatment or prophylaxis of physiological and / or pathophysiological conditions in mammals, preferably humans, that are mediated by GHS receptors. The present invention further provides GHS receptor antagonists and agonists that can be used for modulation of these receptors and are useful for treating above conditions, in particular growth retardation, cachexia, short-, medium- and / or long term regulation of energy balance; short-, medium- and / or long term regulation (stimulation and / or inhibition) of food intake; adipogenesis, adiposity and / or obesity; body weight gain and / or reduction; diabetes, diabetes type I, diabetes type II, tumor cell proliferation; inflammation, inflammatory effects, gastric postoperative ileus, postoperative ileus and / or gastrectomy (ghrelin replacement therapy).

Triazole derivatives and pharmaceutical compositions containing the derivatives are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase Axl. Methods of using the derivatives in treating diseases or conditions associated with Axl catalytic activity are also disclosed.

It is an object of the present invention to provide a novel triazole derivative. Further, it is another object of the present invention to provide a light-emitting element having high luminous efficiency with the use of the novel triazole derivative. Moreover, it is still another object of the present invention to provide a light-emitting device and electronic devices which have low power consumption. A light-emitting element having high luminous efficiency can be manufactured with the use of a triazole derivative which is a 1,2,4-triazole derivative, in which an aryl group or a heteroaryl group is bonded to each of 3-position, 4-position, and 5-position, and in which any one of the aryl group or heteroaryl group has a 9H-carbazol-9-yl group.

Disclosed here in are compounds and methods of diagnosing Alzheimer's Disease or a predisposition thereto in a mammal, the method comprising administering to the mammal a diagnostically effective amount of a radiolabeled compound, wherein the compound is selected from the group consisting of radiolabeled carbazoles and derivatives thereof and triazoles derivatives, allowing the compound to distribute into the brain tissue, and imaging the brain tissue, wherein an increase in binding of the compound to the brain tissue compared to a normal control level of binding indicates that the mammal is suffering from or is at risk of developing Alzheimer's Disease.

Objects are to provide the following: a substance that facilitates hole injection and has high triplet excitation energy; a light-emitting element having high emission efficiency using the substance that facilitates hole injection and has high triplet excitation energy; a light-emitting element having low driving voltage; and a light-emitting device, an electronic device, and a lighting device having low power consumption. Provided is a triazole derivative in which a dibenzothiophen-4-yl or dibenzofuran-4-yl group represented by General Formula (G2) is bonded to any one of Ar1 to Ar3 of a triazole derivative represented by General Formula (G1). In the formulae, A represents oxygen or sulfur, Ar1 to Ar3 separately represent a substituted or unsubstituted aryl group having 6 to 13 carbon atoms, and R1 to R7 separately represent hydrogen, an alkyl group having 1 to 4 carbon atoms, or a substituted or unsubstituted aryl group having 6 to 13 carbon atoms.

The present invention relates to 2-[3-(2,2-Difluoro-benzo[1,3]dioxol-5-ylamino)-5-(2,6-dimethyl-pyridin-4-yl)-[1,2,4]triazol-1-yl]-N-ethyl-acetamide and analogues or pharmaceutically acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy.The invention particularly relates to a potent positive allosteric modulator of nicotinic acetylcholine receptors which have the capability of increasing the efficacy of nicotinic receptor agonists.

The present invention relates to compositions and methods for treating a disease in an animal, which disease is responsive to inhibiting of functional cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide by administering to a mammal in need thereof an effective amount of a compound defined herein (including those compounds set forth in Tables 1-2 or encompassed by formulas I-II) or compositions thereof, thereby treating the disease. The present invention particularly, relates to a method of treating diarrhea and polycystic kidney disease.

The invention relates to an ester type fire-resistant hydraulic fluid. The hydraulic fluid comprises the following raw materials by weight percent: 95-99% of base oil, 1.0-5.0% of diphenol propane, 0.005% of dimethylsilicone fluid or dimethylsilicone grease, 0.05% of tricresyl phosphate, 0.1% of benzotriazole, 100 parts per million (PPM) demulsifying agent T1001 or LZ5957 and 0.2-0.3% of triazole derivative, thiadiazole derivative, N-salicylidene ethylamine, N, N'-bis(salicylidene)ethylenediamine, N, N'-bis(salicylidene)propylene diamine or ethylenediamine tetraacetic acid. A preparation method of the ester type fire-resistant hydraulic fluid comprises the following steps of sufficiently and evenly stirring various materials at room temperature according to a formula, and then filtering. The ester type fire-resistant hydraulic fluid has the beneficial effects that the high temperature use performance of the product is greatly improved, the service life of a hydraulic system and the oil changing period of oils are prolonged, and the ester type fire-resistant hydraulic fluid has a good flame-retardant effect and is safe to use. The preparation method has the advantages that operation is convenient, technology and equipment are simple, energy consumption is low, cost is low, and the like.

The present invention relates to novel triazole compounds of formula (I), thie pharmaceutically acceptable salts and their pharmaceutical compositions, where all symbols have meaning as defined in the description, for use in the treatment of bacterial infections.

The present invention is a lubricant or functional fluid additive for a polyolefin oil blend, comprising a mixture of: (a) an anti-wear component consisting essentially of 95% isopropylated triarylphosphate and 5% dodecyl phosphate, the dodecyl phosphate being only partially esterified, the anti-wear component present in the polyolefin oil blend in a range of from about 0.75 percent to about 2.00 percent by weight; (b) an antioxidant component selected from the group consisting of alkylated phenyl-alpha-naphthylamine, phenyl-alpha-naphthylamine and mixtures thereof, and present in the polyolefin oil blend in a range of from about 0.75 percent to about 2.00 percent by weight; (c) an anti-rust component comprising an alkylated succinic acid ester anti-rust agent, and present in the polyolefin oil blend in a range of from about 0.050 percent to about 0.125 percent by weight; and (d) a metal deactivator component comprising a tolytriazole derivative, and present in the polyolefin oil blend in a range of from about 0.050 percent to about 0.125 percent by weight.

The present invention relates to formulations for corrosion-inhibiting, emulsifying, lubricating or as a surfactant in organic hydrocarbon and / or water based system containing an acyl amino acid derivative and a triazole derivative.

The present invention relates to a thrombin receptor antagonist containing a compound represented by the formula (I)wherein R1a, R1b and R2 are each a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group, or an optionally substituted alkoxy, R3 is a group represented by the formula —NHCOR4, —NHSO2R5, —NHCON(R6a)(R6b), —NHCOOR7 or —CONHR8 wherein R4, R5, R6a, R6b, R7 and R8 are each a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group and the like), ring A is monocyclic aromatic ring optionally further having substituent(s), R1a and R1b are optionally bonded to each other to form an optionally substituted nitrogen-containing non-aromatic heterocycle, or a salt thereof or a prodrug thereof. The thrombin receptor antagonist of the present invention has a thrombin receptor (particularly PAR-1) antagonistic action and is useful for the prophylaxis or treatment of PAR-1 mediated pathological condition or disease.

A substance that facilitates hole injection and has high triplet excitation energy is provided. A light-emitting element having high emission efficiency is provided. A light-emitting element driven with a low voltage is provided. Or a light-emitting element having a long lifetime is provided. Provided is a light-emitting element including a triazolo[4,3-f]phenanthridine derivative or a triazolo[3,4-a]isoquinoline derivative. Provided is a triazolo[4,3-f]phenanthridine and triazolo[3,4-a]isoquinoline derivatives, which are novel and can be used for the light-emitting element.

Disclosed here in are compounds and methods of diagnosing Alzheimer's Disease or a predisposition thereto in a mammal, the method comprising administering to the mammal a diagnostically effective amount of a radiolabeled compound, wherein the compound is selected from the group consisting of radiolabeled flavones, coumarins, carbazoles, quinolinones, chromenones, imidazoles and triazoles derivatives, allowing the compound to distribute into the brain tissue, and imaging the brain tissue, wherein an increase in binding of the compound to the brain tissue compared to a normal control level of binding indicates that the mammal is suffering from or is at risk of developing Alzheimer's Disease

The core structure of 2-(1',2',3'-triazole-4'-benzyloxy)-1,3,4,6-O-acetyl-D-glucose with an anti-colorectal carcinoma activity is that a 1,2,4-triazole derivative substitutes 2-site of 1,3,4,6-O- acetyl-D-glucose. The above compound has a good activity of inhibiting colorectal carcinoma cells, and can be used as an anti-colorectal carcinoma medicine. A synthesis method of the above compound comprises the following steps: 2-amino-D-glucose hydrochloride and an azidation reagent are used as raw materials to generate a 2-azido-1,3,4,6-O-acetyl-D-glucose intermediate under an alkaline condition; 3-propargyl bromide and phenylcarbinol react under the action of sodium hydride to generate phenyl propargyl ether; and the 2-azido-1,3,4,6-O-acetyl-D-glucose intermediate and phenyl propargyl ether undergo a click reaction in a solvent under the catalysis of monovalent copper to generate 2-(1',2',3'-triazole-4'-benzyloxy)-1,3,4,6-O-acetyl-D-glucose.

Provided are triazole derivatives of Formula I which are potent inhibitors of spleen tyrosine kinase and pharmaceutical composition. The triazole derivatives are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD, rheumatoid arthritis, and cancer.

The invention relates to a 1206 lubricating grease, comprising the following components by weight percent: 2-4% of aluminum isopropoxide, 4-6% of aminated bentonite, 3-5% of stearic acid, 1-3% of benzoic acid, 37-41% of viscous oil in refined naphthenic base, 29-43% of viscous oil in refined paraffin base, 1-3% of zinc dialkyl dithiophosphate, 1.6-2.9% of triazole fatty acid ammonium salt, 0.1-0.5% of a triazole derivative, 0.8-1.8% of tricresyl phosphate, 1.2-5% of polyisobutene and 0.7-1% of ethyl carbamate. Compared with the prior art, the 1206 lubricating grease is high in dropping point, large in sintering load data and relatively good in compression and wear resistance, and the more outstanding feature is as follows: the steel mesh is excellent in oil dividing, the embodiment 3 is 1 / 10 of the 1275 grease of LE company of America, and the embodiment 1 is not greater than 1 / 8; obviously, the pollution in the operation is smaller, the resource can be saved more, and the operation period of the equipment can be prolonged.